Scadenza: 7 September 2022
Topic:
roposals should address all of the following:
- Design and conduct randomised or cluster-randomised academic investigator-initiated pragmatic clinical trials to deliver effective and evidence-based treatment interventions for implementation by healthcare systems at the level of local communities, EU Regions, Member States and Associated Countries, taking into account socio-economic and biological stratification, such as biology of the disease, gender, cancer stage, and age.
- The chosen treatment intervention(s)[2] should be adapted to the particular needs of the target population and to the specificities of the provision of care at local, regional, or national level, duly reflecting the diversity across Member States and Associated Countries. Furthermore, affordability and accessibility should be taken into account.
- The successful proposals will address treatment interventions for patients with refractory cancers (cancers with a 5-year overall survival of less than 50% from time of diagnosis) at any stage of the disease, for any cancer subtype, in any age group or part of society.
- The successful proposals should clearly justify and describe the evidence supporting the chosen treatment intervention.
- The primary and secondary endpoints of the pragmatic clinical trial should target overall survival, patient-preferred clinical benefit, patient-reported outcomes and quality of life issues considered important by and for cancer patients and their caregivers. Such endpoints should be defined together with patients and their caregivers through research models that use open knowledge, (social) innovation systems and support end-user engagement (e.g. living labs).
- Implementers of pragmatic clinical trials and trial results should include physicians, academia, patients and their caregivers, patient representatives, payers, charities and foundations, research organisations, civil society, regional and national research and innovation organisations, and health authorities.
- Successful pragmatic clinical trials, including their analyses, should be completed within 5 years after the start of the project. Translational research is not within the scope of this topic.
In all instances, sex- and gender-related issues must be taken into account. All data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of socio-economic status.
Programma:
HORIZON-RIA HORIZON Research and Innovation Actions
Ente finanziatore:
EU
Budget complessivo:
€ 60 milion
Who can participate:
To be eligible for funding, applicants must be established in one of the eligible countries, i.e.:
– the Member States of the European Union, including their outermost regions;
– the Overseas Countries and Territories (OCTs) linked to the Member States;
– eligible non-EU countries:
– countries associated to Horizon Europe;
– low- and middle-income countries
Partnership: Mandatory
Status:
Closed
Quota finanziabile:
100%
Topic:
roposals should address all of the following:
- Design and conduct randomised or cluster-randomised academic investigator-initiated pragmatic clinical trials to deliver effective and evidence-based treatment interventions for implementation by healthcare systems at the level of local communities, EU Regions, Member States and Associated Countries, taking into account socio-economic and biological stratification, such as biology of the disease, gender, cancer stage, and age.
- The chosen treatment intervention(s)[2] should be adapted to the particular needs of the target population and to the specificities of the provision of care at local, regional, or national level, duly reflecting the diversity across Member States and Associated Countries. Furthermore, affordability and accessibility should be taken into account.
- The successful proposals will address treatment interventions for patients with refractory cancers (cancers with a 5-year overall survival of less than 50% from time of diagnosis) at any stage of the disease, for any cancer subtype, in any age group or part of society.
- The successful proposals should clearly justify and describe the evidence supporting the chosen treatment intervention.
- The primary and secondary endpoints of the pragmatic clinical trial should target overall survival, patient-preferred clinical benefit, patient-reported outcomes and quality of life issues considered important by and for cancer patients and their caregivers. Such endpoints should be defined together with patients and their caregivers through research models that use open knowledge, (social) innovation systems and support end-user engagement (e.g. living labs).
- Implementers of pragmatic clinical trials and trial results should include physicians, academia, patients and their caregivers, patient representatives, payers, charities and foundations, research organisations, civil society, regional and national research and innovation organisations, and health authorities.
- Successful pragmatic clinical trials, including their analyses, should be completed within 5 years after the start of the project. Translational research is not within the scope of this topic.
In all instances, sex- and gender-related issues must be taken into account. All data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of socio-economic status.
Who can participate:
To be eligible for funding, applicants must be established in one of the eligible countries, i.e.:
– the Member States of the European Union, including their outermost regions;
– the Overseas Countries and Territories (OCTs) linked to the Member States;
– eligible non-EU countries:
– countries associated to Horizon Europe;
– low- and middle-income countries
Programme:
HORIZON-RIA HORIZON Research and Innovation Actions
Consortium: Required
Status: Open
Total budget:
€ 60 milion
Funding rate:
100%
Notes:
The Commission estimates that an EU contribution of between EUR 4.00 and 6.00 million would allow these outcomes to be addressed
appropriately.
